I
Ionpath
Health Tech & Medtech · Menlo Park, United States · Founded 2014
Enabling precision medicine through high-definition spatial proteomics MoreLess
Ionpath, Inc. operates in the biotechnology sector, specializing in high definition spatial proteomics. The company has developed a multiplexed ion beam imaging (MIBI) platform that surpasses traditional immunohistochemistry (IHC) methods. This platform enables researchers and clinicians to gain a deeper understanding of the tissue microenvironment through highly multiplexed, quantitative single cell analysis. Ionpath's technology is particularly valuable for identifying responder populations, predicting patient responses, and informing therapeutic selection. The company's primary clients include academic research institutions, pharmaceutical companies, and clinical laboratories. Ionpath generates revenue through the sale of its imaging platforms, consumables, and related services. The market it operates in is the rapidly growing field of precision medicine and advanced diagnostics. Keywords: spatial proteomics, tissue imaging, single cell analysis, multiplexed ion beam imaging, tumor microenvironment, quantitative analysis, clinical grade repeatability, therapeutic selection, biotechnology, precision medicine.
Company overview
Ionpath company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Menlo Park, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 63.5
Valuation & funding
Ionpath funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2022 | $0 | — | Thermo Fisher Scientific | ↗ |
| SERIES B✓Equity / VC | Sep 2020 | $18M | $72M | +ND Capital · Genoa Ventures · Samsara BioCapital · Bruker | — |
| SERIES AEquity / VC | Jan 2018 | $0 | — | Undisclosed | — |
| SEEDEquity / VC | Oct 2015 | — | — | Genoa Ventures | — |
| SPINOUT✓Other financing | Jan 2014 | $0 | — | Stanford University | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 11 |
| 2025 | 14 |
| 2024 | 32 |
| 2023 | 40 |
| 2022 | 59 |
| 2021 | 47 |
| 2020 | 45 |
Growth signals
Ionpath website traffic
Latest recorded traffic for Ionpath is 1.1K monthly website visits, up 120% over the last three months. Ionpath's team declined 21.4% over the past year.
Comparisons
Ionpath compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Ionpath's talent
Source: Dealroom Talent Intelligence.
Investors
11 investors on Ionpath's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Ionpath has talent and traffic
team presence
In the news
Latest news about Ionpath
Recent press, funding announcements, and product moves mentioning Ionpath — open to read from the original sources.
Market sentiment
What the market is saying about Ionpath
An AI-synthesized read of the highest-engagement posts about Ionpath on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ionpath’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.